[Sofo/Riba GT1] Your explanation is consistent with the information
The irony here is this oral combo isn't viable in either GT1 or GT3. There's no late-stage data to support the GT1 filing. Why wouldn't GILD run a GT2 study in Russia? This is the only genotype this combo works well in.
Market Data 
Markets 
AI
